Clinical Trial Update: Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of eribulin with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Eisai Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-03-30